Skip to content
Subscribe

FDA Approves New Drug To Prevent HIV

Published:
prevent-HIV

The FDA approved the use of a drug designed to prevent at-risk adults from attaining HIV for the first time. Truvada, an antiretroviral medication, was FDA approved in 2004 for the usage to help control HIV in already infected patients. However, studies prove uninfected partners of people with HIV who take Truvada, reduce the possibility of transmission of the virus up to 96%.

Despite Truvada’s significant findings, health professionals insist that Truvada alone is not the answer to the prevention of HIV infection. Usage of Truvada should be in combination with other safe sex practices.

Dr. Anthony Fauci, the director of the National Institute for Allergy and infections Diseases at the National Institutes of Health, believes the FDA approval monumental in HIV treatment and research, but also is wary of potential public interpretation of the drug.

“The approval of Truvada to prevent HIV infection in uninfected individuals who are at high risk of sexually acquired HIV infection is a significant development, providing an important addition to our toolkit of HIV prevention interventions," he said.

"However, it is critical to stress that Truvada as ‘pre-exposure prophylaxis’ should not be considered a stand-alone method, but should be used in conjunction with other proven HIV prevention strategies such as condom use, risk-reduction counseling, and frequent HIV testing.”

Gilead Sciences Inc., the corporation accredited with producing Truvada, says the drug is the “most-prescribed antiretroviral medication in the country.”

Norbert Bischofberger, Executive Vice President, Research and Development and Chief Scientific Officer of Gilead Sciences, Inc., made a statement to CNN about the FDA’s approval:

“Today’s decision is the culmination of almost 20 years of research involving investigators, academic and medical institutions, funding agencies and nearly 20,000 trial participants around the world, and Gilead is proud to have been a partner in this effort.”

Despite Truvada’s emergence as a preventative HIV treatment, the AIDS Healthcare Foundation made a statement disapproving of the FDA’s recent decision:

“From the beginning, we believe there was a rush to judgment by government officials and others in favor of such approval despite decidedly mixed studies offered in support."

Critics also cite the steep cost of the drug, one year's supply can $11,000, as an additional hurdle.

Despite this, Truvada is an immense step in treatment options for HIV, and has many wondering if a future ‘cure’ is plausible at this point in time.

Frontline recently debuted, Endgame: AIDS in Black America, a televised documentary piece, revisiting the historical roots of AIDS in the United States, the importance of awareness still, and the projected future of the virus and treatment.  Moreover, the piece reveals keen insight in how HIV/AIDS has majorly impacted black America.

Aids.gov, the United States government’s official information HIV/AIDS websites reports current statistics. A sometimes, common misconception that HIV/AIDS used to be a problem, is wrong. Today, AIDS still affects millions of Americans as well as millions worldwide.

  • Every 9.5 minutes someone in the United States is infected with HIV
  • More than one million people are living with HIV in the U.S.
  • 1 in 5 (20%) living with HIV are unaware of their infection
  • Gay and bisexual men of all races are the most severely affected by HIV
  • Among racial/ethnic groups, African Americans face the most severe burden of HIV in the U.S.
  • Blacks represent approximately 14% of the U.S. population, they accounted for almost half (46%) of people living with HIV in the U.S. in 2008, as well as an estimated 44% of new infections in 2009. HIV infections among blacks over have been roughly stable since the early 1990s.
  • More than 17,000 people with AIDS in the U.S. died in 2009 and more than 619,000 people with AIDS the U.S. have died since the epidemic began.

According to PBS Newshour, in Tanzania and three other African sites, the United States and its African partners will be launching a “combination of coordinated HIV prevention tools and strategies in the coming months that will test what President Obama and Secretary of State Hillary Clinton have been telling the world: An AIDS-free generation is now possible because the tools to prevent HIV infection are at hand.”

Recently the Government Accountability Office report released findings indicating AIDS funding has decreased.

In regard to diminished Federal government AIDS funding, Frontline cited:

“The report comes as advocates and officials have said that despite increases in federal funding for HIV/AIDS, there still isn’t enough money to ensure everyone in the U.S. gets care. Federal and state budgets, already hammered by the recession, have been stretched as more people are living longer with the disease and more become infected.”

Recent research advancements in HIV/AIDS treatment, such as the new found use for the drug Truvada, optimistically suggests better treatment and medical options are to come. However, funding, and continuous ongoing spread of the HIV infection remains fact. The end may be in sight, but there are still existing challenges in how that ‘end’ is achieved.

Adhere to the IVN etiquette

By posting a comment, you agree to adhere to our etiquette rules: No partisan attacks, no personal attacks, substantiate your sources, no self-promotion.

Contact IVN

Questions about this article or our coverage? Send us a message. A free IVN member account is required.

Message sent

Thanks, we’ll review it and get back to you if needed.

Message not sent

Sorry, something went wrong. Please try again.

Sign in to send a message

Messages are tied to your IVN member account. Signing in is free and takes a few seconds.

Contact IVN

Questions about this article or our coverage? Send us a message. A free IVN member account is required.

Message sent

Thanks, we’ll review it and get back to you if needed.

Message not sent

Sorry, something went wrong. Please try again.

Sign in to send a message

Messages are tied to your IVN member account. Signing in is free and takes a few seconds.

Republish this article

Republishing guidelines

Republish IVN articles for free. Independent Voter News articles may be republished online or in print under a Creative Commons BY-NC-ND 4.0 license, on these terms:

  1. Credit the author and IVN. Keep the byline ("By Author Name, Independent Voter News") and the attribution note at the end, which links to the original.
  2. Keep the meaning. You may update time and place references and apply your house style. You may trim for length, as long as the cuts don't change the meaning or misrepresent the author. Keep the headline. Mark any additions as your own (for example "Additional reporting by ...").
  3. Translations are welcome. Translate faithfully, add "Translated from English by [your outlet]", and tell us at editor@ivn.us.
  4. Keep the links, including the link to the original article.
  5. Keep the tracking image. The HTML includes a 1-pixel image that counts readers on your page. It collects no personal information.
  6. Photos and illustrations. Images credited to IVN may be used with this article only. Images credited to others (AP, Getty, Unsplash, Wikimedia and so on) stay under their owners' terms. Secure the rights or switch "Include images" off.
  7. Don't sell it. You can't sell our articles or sell ads specifically against them. Your normal site advertising is fine.
  8. No implied endorsement. Don't suggest that IVN or the author endorses you, your candidates or your causes, or that donations to you support IVN.
  9. Keep labels. Opinion or analysis pieces keep that label.
  10. Point search engines to the original. Where your CMS allows, set the canonical URL to the original IVN article.
  11. No bulk or automated republishing, and don't submit our articles to aggregators (Apple News, Google News, MSN) as your own.
  12. Corrections and removals. Update your copy when we correct it, and remove it promptly if we ask. We'll contact you at the email you give us.
  13. Questions or print republication: editor@ivn.us.

IVN staff: fill in who you're inviting above, then create the invite.

Preparing the article

FDA Approves New Drug To Prevent HIV

Choose a format
  • HTML
  • Email HTML
  • Markdown
  • Formatted (.docx)
  • Plain text
  • WordPress blocks
  • PDF
Choose a platform

Photos credited to others need their owners' permission.

To for

Republishing somewhere else? Questions? editor@ivn.us